Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Transcode Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 13 | 13 | 0 |
| Shares | 1.09M | 2.08M | +995.2K (+91.3%) |
| Value | $3.14M | $2.67M | −$473.0K (−15.1%) |
New holders (2)
Institutions that held Transcode Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AIGH Capital Management LLC | 1,289,000 | $1.62M | 0.67% |
| Renaissance Technologies LLC | 19,600 | $25.0K | 0.00% |
Sold out (2)
Institutions that held Transcode Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Kepos Capital LP | 275,000 | $792.0K |
| UBS Group AG | 3,973 | $11.0K |